Serenis and three other independent clinics have acquired Clinique du Chateau de Vernhes
April 2022 — Groupe Serenis and three other independent clinics have acquired Clinique du Chateau de Vernhes from the funding family.
Led by Groupe Serenis, along with Clinique Aufréry, Clinique Verdaich and Clinique des Pyrénées, the transaction has been structured as an LBO takeover, involving several financing partners, including private debt funds Zencap AM and GSO Financement, and supported by a senior debt financing provided by CIC bank. Real estate has been outsourced to Swiss Life AM.
Clinique du Chateau de Vernhes specializes in the treatment of obesity and its complications. It was founded in 1964 in Bondigoux, France, and is located in a 17th century castle on the edge of the Tarn, in the heart of a vast park, conducive to physical activity. Its medical and paramedical team offer personalized care to its patients.
Our role in the transaction
Oaklins’ team in France advised the group of acquirors. The team conducted negotiations with the seller, structured financing requirements and reorganized real estate ownership.
Sprechen Sie mit dem Deal Team
Transaktionen
Cibus has acquired Aweta from Standard Investment
Standard Investment has reached an agreement with Cibus Capital, advisor to the Cibus funds, on the sale of Aweta, a global leader in fruit and vegetable sorting, grading and packing equipment. Completion of the transaction is expected in the coming weeks. The transaction provides Aweta with a strong partner to support the company’s next growth phase. Under Cibus’ ownership, Aweta will pursue further international growth and accelerate investment in R&D, supporting the installed base and product innovation, including software and AI capabilities. Aweta’s leadership team will continue to lead the business.
Mehr erfahrenKatalyst Diagnostics has been acquired by Cruinn Diagnostics
Katalyst Diagnostics Ltd. has been acquired by Cruinn Diagnostics Ltd. The acquisition strengthens Cruinn Diagnostics’ presence in the UK diagnostics market, adding established NHS customer relationships, local commercial infrastructure and a complementary portfolio of point-of-care diagnostic solutions. It also creates opportunities to introduce Cruinn Diagnostics’ products to UK customers while leveraging its established Irish platform to accelerate the growth of Katalyst Diagnostics’ portfolio in Ireland. With more than 100 employees and revenues in excess of US$56 million, the combined business will continue to focus on the UK market, where Cruinn Diagnostics sees significant opportunities to expand through further investment and targeted M&A.
Mehr erfahrenGroGlass has been acquired by Apogee Enterprises
Apogee Enterprises, Inc. (Nasdaq: APOG), a leading US provider of architectural building products, services and high-performance coated materials, has acquired GroGlass, a Latvia-based developer and manufacturer of high-performance anti-reflective and UV-protective glass coatings. The acquisition brings GroGlass’ differentiated coating technologies and materials science expertise into Apogee’s performance surfaces segment, broadening its product offering and market reach while expanding its manufacturing and R&D presence in Europe.
Mehr erfahren